Sareum Holdings PLC's (LON:SAR) Tim Mitchell tells Proactive London's Andrew Scott they're advancing initial discussions with potential licensees for its pre-clinical tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitor immunotherapies for autoimmune diseases and cancer. He says they're looking to complete investigational new drug-enabling work for at least one of its TYK2/JAK1 candidates by the end of the calendar year with a decision on an initial target to be made in the second half.
Sareum Holdings focused on striking a deal for its immunotherapies
Quick facts: Sareum Holdings PLC
Price: 0.8 GBX
Market Cap: £26.04 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE